FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283460892> ?p ?o ?g. }

• W4283460892 endingPage "1626" @default.
• W4283460892 startingPage "1619" @default.
• W4283460892 abstract "What is known and objective Patients with low-risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) often need transfusions, which may accelerate iron overload. The aim of this study was to evaluate the efficacy, safety and dose–effect relationships of deferasirox (DFX) in patients with low-risk MDS and AA who were refractory to regular treatment in a real-world setting. Methods Patient data were recorded, and dose–effect relationships of DFX were calculated after the first 6 months. Total annual exposure to DFX was calculated after 12 months and expressed as the accumulated exposure time at a dosage of 20 mg/kg/day. Results and discussion Sixty-one patients with low-risk MDS and 51 with AA were enrolled. The minimum dosage of DFX needed for a significant serum ferritin (SF) decrease was 20 mg/kg/day at 6 months, and the minimum accumulation of DFX had to reach 9 months at 20 mg/kg/day by 12 months for patients with low-risk MDS. For patients with AA, the minimum dosage was 10 mg/kg/day at 6 months, and the minimum accumulation had to reach 3 months at 20 mg/kg/day by 12 months. With the same exposure, significant improvements in haematological parameters were also observed in AA. Lower liver enzymes compared with baseline were observed. Gastrointestinal disorders and elevated serum creatinine were the most common side effects. Higher exposure to DFX correlated with longer overall survival (OS). What is new and conclusion A significant decrease in SF and an improvement in haematologic parameters, organ function and even OS can be achieved if the accumulated DFX dose reaches a certain level. Patients with low-risk MDS need a higher dose than those with AA." @default.
• W4283460892 created "2022-06-26" @default.
• W4283460892 creator A5000313237 @default.
• W4283460892 creator A5049559718 @default.
• W4283460892 date "2022-06-24" @default.
• W4283460892 modified "2023-09-26" @default.
• W4283460892 title "Dose of deferasirox correlates with its effects, which differ between low‐risk myelodysplastic syndrome and aplastic anaemia" @default.
• W4283460892 cites W1484640986 @default.
• W4283460892 cites W1510055678 @default.
• W4283460892 cites W1914774283 @default.
• W4283460892 cites W1926532043 @default.
• W4283460892 cites W1942096880 @default.
• W4283460892 cites W1952193752 @default.
• W4283460892 cites W1994868666 @default.
• W4283460892 cites W2016436057 @default.
• W4283460892 cites W2023231296 @default.
• W4283460892 cites W2035570385 @default.
• W4283460892 cites W2064612590 @default.
• W4283460892 cites W2074001235 @default.
• W4283460892 cites W2086820492 @default.
• W4283460892 cites W2100714797 @default.
• W4283460892 cites W2109076483 @default.
• W4283460892 cites W2129510594 @default.
• W4283460892 cites W2131540408 @default.
• W4283460892 cites W2131755661 @default.
• W4283460892 cites W2157872347 @default.
• W4283460892 cites W2166892083 @default.
• W4283460892 cites W2593505615 @default.
• W4283460892 cites W2752052652 @default.
• W4283460892 cites W2904391185 @default.
• W4283460892 cites W4249395130 @default.
• W4283460892 doi "https://doi.org/10.1111/jcpt.13712" @default.
• W4283460892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35748618" @default.
• W4283460892 hasPublicationYear "2022" @default.
• W4283460892 type Work @default.
• W4283460892 citedByCount "0" @default.
• W4283460892 crossrefType "journal-article" @default.
• W4283460892 hasAuthorship W4283460892A5000313237 @default.
• W4283460892 hasAuthorship W4283460892A5049559718 @default.
• W4283460892 hasConcept C121332964 @default.
• W4283460892 hasConcept C126322002 @default.
• W4283460892 hasConcept C141071460 @default.
• W4283460892 hasConcept C142424586 @default.
• W4283460892 hasConcept C2777799968 @default.
• W4283460892 hasConcept C2780007613 @default.
• W4283460892 hasConcept C2780306776 @default.
• W4283460892 hasConcept C2780817109 @default.
• W4283460892 hasConcept C2781053155 @default.
• W4283460892 hasConcept C2781440808 @default.
• W4283460892 hasConcept C71924100 @default.
• W4283460892 hasConcept C87355193 @default.
• W4283460892 hasConcept C90924648 @default.
• W4283460892 hasConceptScore W4283460892C121332964 @default.
• W4283460892 hasConceptScore W4283460892C126322002 @default.
• W4283460892 hasConceptScore W4283460892C141071460 @default.
• W4283460892 hasConceptScore W4283460892C142424586 @default.
• W4283460892 hasConceptScore W4283460892C2777799968 @default.
• W4283460892 hasConceptScore W4283460892C2780007613 @default.
• W4283460892 hasConceptScore W4283460892C2780306776 @default.
• W4283460892 hasConceptScore W4283460892C2780817109 @default.
• W4283460892 hasConceptScore W4283460892C2781053155 @default.
• W4283460892 hasConceptScore W4283460892C2781440808 @default.
• W4283460892 hasConceptScore W4283460892C71924100 @default.
• W4283460892 hasConceptScore W4283460892C87355193 @default.
• W4283460892 hasConceptScore W4283460892C90924648 @default.
• W4283460892 hasIssue "10" @default.
• W4283460892 hasLocation W42834608921 @default.
• W4283460892 hasLocation W42834608922 @default.
• W4283460892 hasOpenAccess W4283460892 @default.
• W4283460892 hasPrimaryLocation W42834608921 @default.
• W4283460892 hasRelatedWork W1510055678 @default.
• W4283460892 hasRelatedWork W2024338366 @default.
• W4283460892 hasRelatedWork W2035570385 @default.
• W4283460892 hasRelatedWork W2320817941 @default.
• W4283460892 hasRelatedWork W2528057197 @default.
• W4283460892 hasRelatedWork W2533396190 @default.
• W4283460892 hasRelatedWork W2904391185 @default.
• W4283460892 hasRelatedWork W2972868070 @default.
• W4283460892 hasRelatedWork W3213405148 @default.
• W4283460892 hasRelatedWork W4249752330 @default.
• W4283460892 hasVolume "47" @default.
• W4283460892 isParatext "false" @default.
• W4283460892 isRetracted "false" @default.
• W4283460892 workType "article" @default.